Seaport Therapeutics seeks $212.4 million in US IPO

1 articles · Updated · Bloomberg · Apr 27

The Boston-based biotech plans to offer 11.8 million shares at $16 to $18 each, targeting a $912 million valuation.
Funds raised will support Seaport’s clinical-stage development of antidepressant and anxiety drugs, according to its SEC filing on Monday.
Seaport Therapeutics aims to strengthen its position in the mental health drug market as it advances its pipeline through pivotal clinical trials.

Is Seaport's IPO a strategic move to attract a Big Pharma acquisition before its pivotal trial results?

With $233M in cash, why is Seaport pursuing a risky IPO now instead of waiting for key data?

How could a government shutdown impact Seaport's IPO timeline and its crucial clinical trials?

Will Seaport's lead drug work for patients who don't respond to today's standard treatments?

How does Seaport's Glyph™ platform promise to overcome the side effects of current antidepressants?